A Study of JNJ-87890387 for Advanced Solid Tumors

This study is testing a drug called JNJ-87890387, which works by immunotherapy (using your body's immune system to fight cancer). It's for people with advanced solid tumors, specifically certain types of kidney, ovarian, uterine, colorectal, or lung cancer that have spread or cannot be removed by surgery. The main goals are to find a safe dose of JNJ-87890387 and to understand its side effects. We are looking for about 200 participants aged 18 and older. The current recruitment status is unclear.

Study design: This study plans to enroll 200 participants. It is an interventional study, meaning participants will receive the study drug.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be monitored for adverse events (side effects) for up to 2 years and 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of JNJ-87890387 for Advanced Solid Tumors

Recruiting

PHASE1Ages 18+InterventionalTreatment

Janssen Research & Development, LLC

~200 participants

Updated 2026-08-28 on ClinicalTrials.gov

What's tested:JNJ-87890387

At a glance

Recruiting sites

6 of 6 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)

Measured over Up to first 21 days after administration of the first full treatment dose

+1 more outcome measured

Conditions

Neoplasms

Advanced Solid Tumors

Where it's being run

6 sites across 4 states

France2

Spain2

Michigan1

Tennessee1

Study leadership

Janssen Research & Development, LLC Clinical Trial · STUDY_DIRECTOR · Janssen Research & Development, LLC

Who to contact

Study Contact

[email protected]

844-434-4210

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) Renal cell cancer (RCC)-clear cell or papillary carcinoma; b) Endometrioid ovarian cancer c) Endometrioid uterine carcinoma; d) Colorectal adenocarcinoma (CRC); e) Lung adenocarcinoma

Have measurable or evaluable disease: Part 1- Either measurable or evaluable disease; Part 2- At least 1 measurable lesion per RECIST v1.1. Participants with ovarian cancer without a measurable lesion must have disease evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or have cancer antigen (CA) 125 greater than (\>) 2\*upper limit of normal (ULN) during screening

All participants in Part 1 and Part 2 must consent to provide an archived tumor tissue sample at screening

Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening

Be willing and able to adhere to the lifestyle restrictions specified in this protocol.

Exclusion

Active Central Nervous System (CNS) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \[\<=\]10 milligrams \[mg\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment

Toxicity from prior anticancer therapy that has not resolved to Grade \<=1 (except alopecia, vitiligo, Grade \<=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement)

History of Grade greater than or equal to (\>=) 2 immune-related AE(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of Grade 2 and Grade 3 immune-related AEs that responded to treatment and that did not recur following rechallenge. Endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed.

History of solid organ or hematologic stem cell transplantation

Any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment

What this trial measures

Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)Up to first 21 days after administration of the first full treatment dose
Number of participants with DLTs will be reported. The DLTs are adverse events including certain high grade non-hematologic or hematologic toxicities, or toxicities meeting other specific criteria.
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by SeverityUp to 2 years 9 months
An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome events (ICANS), which will be graded by American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.

Trialytics